Table 1.
Baseline demographic and clinical characteristics of patients who received 1L treatment for locally advanced or metastatic MCC
| Demographic or clinical characteristic | Overall (n = 94) | Avelumab (n = 28) | Non‐avelumab IO (n = 26) | Chemotherapy (n = 40) |
|---|---|---|---|---|
| Age at 1L treatment initiation, median (range), years | 73 (21–90+) | 78 (52–90+) | 74 (43–90+) | 69 (21–90+) |
| Age group, n (%) | ||||
| <65 years | 20 (21.3) | 3 (10.7) | 4 (15.4) | 13 (32.5) |
| 65–74 years | 34 (36.2) | 7 (25.0) | 9 (34.6) | 18 (45.0) |
| 75+ years | 40 (42.6) | 18 (64.3) | 13 (50.0) | 9 (22.5) |
| Male, n (%) | 64 (68.1) | 24 (85.7) | 15 (57.7) | 25 (62.5) |
| Race, n (%) | ||||
| White | 78 (83.0) | 23 (82.1) | 22 (84.6) | 33 (82.5) |
| Not documented/Not reporteda | 16 (17.0) | 5 (17.9) | 4 (15.4) | 7 (17.5) |
| U.S. practice region, n (%) | ||||
| South | 40 (42.6) | 16 (57.1) | 12 (46.2) | 12 (30.0) |
| West | 42 (44.7) | 11 (39.3) | 10 (38.5) | 21 (52.5) |
| Northeast | 2 (2.1) | 1 (3.6) | 0 | 1 (2.5) |
| Midwest | 10 (10.6) | 0 | 4 (15.4) | 6 (15.0) |
| Stage at initial MCC diagnosis, n (%) | ||||
| IA–IIIA | 17 (18.1) | 4 (14.3) | 5 (19.2) | 8 (20.0) |
| IIIB | 12 (12.8) | 4 (14.3) | 3 (11.5) | 5 (12.5) |
| IV | 22 (23.4) | 6 (21.4) | 5 (19.2) | 11 (27.5) |
| Not documented | 43 (45.7) | 14 (50.0) | 13 (50.0) | 16 (40.0) |
| Disease status at 1L treatment initiation, n (%) | ||||
| Locally advanced | 27 (28.7) | 9 (32.1) | 8 (30.8) | 10 (25.0) |
| Metastatic | 67 (71.3) | 19 (67.9) | 18 (69.2) | 30 (75.0) |
| Primary tumor location, n (%) | ||||
| Face | 25 (26.6) | 5 (17.9) | 9 (34.6) | 11 (27.5) |
| Lower limb | 19 (20.2) | 6 (21.4) | 5 (19.2) | 8 (20.0) |
| Upper limb | 17 (18.1) | 8 (28.6) | 4 (15.4) | 5 (12.5) |
| Trunk | 10 (10.6) | 4 (14.3) | 3 (11.5) | 3 (7.5) |
| Scalp and neck | 8 (8.5) | 4 (14.3) | 1 (3.8) | 3 (7.5) |
| Unknown primary | 4 (4.3) | 0 | 2 (7.7) | 2 (5.0) |
| Face, other | 1 (1.1) | 0 | 0 | 1 (2.5) |
| Not documented | 9 (9.6) | 1 (3.6) | 2 (7.7) | 6 (15.0) |
| Immunocompromised, n (%) | 7 (7.4) | 1 (3.6) | 3 (11.5) | 3 (7.5) |
| ECOG performance score, n (%) | ||||
| 0 | 15 (16.0) | 2 (7.1) | 4 (15.4) | 9 (22.5) |
| 1 | 37 (39.4) | 14 (50.0) | 9 (34.6) | 14 (35.0) |
| 2 | 17 (18.1) | 3 (10.7) | 4 (15.4) | 10 (25.0) |
| 3 | 1 (1.1) | 0 | 1 (3.8) | 0 |
| Not documented | 24 (25.5) | 9 (32.1) | 8 (30.8) | 7 (17.5) |
| Lactate dehydrogenase, median (range), U/L | 205.5 (87.0–1,815.0) | 206.0 (87.0–854.0) | 217.5 (131.0–552.0) | 205.0 (119.0–1,815.0) |
| Metastatic sites recorded prior to 1L treatment initiation, n (%) | ||||
| Patients with at least 1 recorded metastatic site | 66 (70.2) | 19 (67.8) | 18 (69.2) | 29 (72.5) |
| Lymph nodeb | 38 (57.6) | 10 (55.6) | 11 (57.9) | 17 (58.6) |
| Liverb | 17 (25.4) | 8 (42.1) | 5 (27.8) | 4 (13.3) |
| Boneb | 16 (23.9) | 3 (15.8) | 4 (22.2) | 9 (30.0) |
| Lungb | 3 (4.5) | 2 (10.5) | 0 | 1 (3.3) |
| Brainb | 3 (4.5) | 0 | 1 (5.6) | 2 (6.7) |
| Otherb | 53 (79.1) | 14 (73.7) | 15 (83.3) | 24 (80.0) |
| Time from initial MCC diagnosis to laMCC/mMCC status, median (range), weeks | 5.3 (0.1–239.7) | 5.1 (0.1–239.7) | 6.1 (0.1–155.8) | 4.0 (0.1–190.3) |
| Follow‐up from 1L treatment initiation, median (range), months | 11.0 (0.3–53.8) | 11.2 (0.5–27.2) | 9.8 (0.3–35.9) | 10.7 (0.7–53.8) |
a
Not documented combined with Not reportable because of cell count <5 as per McKesson Life Sciences best practices on reporting race.
b
Percentage among all patients with metastases in treatment cohort.
Abbreviations: 1L, first‐line; ECOG, Eastern Cooperative Oncology Group; IO, immunotherapy; laMCC, locally advanced MCC; MCC, Merkel cell carcinoma; mMCC, metastatic MCC.